Objective: In utero exposure to valproic acid (VPA) has been associated with worse pregnancy outcomes compared to all other antiepileptic drugs. We have previously shown that VPA alters the expression of placental transporters for hormones and nutrients in vitro and in pregnant mice. Here, our aim was to characterize the effects of short exposure to VPA on the expression of carriers for compounds essential for fetal development in human placentas ex vivo, under controlled conditions. Methods: Placentas were obtained from cesarean deliveries of women with no known epilepsy. Cotyledons were cannulated and perfused in the absence or the presence of VPA (42, 83, or 166 lg/mL; n = 6/group) in the maternal perfusate over 180 minutes. A customized gene panel array was used to analyze the expression of carrier genes in the perfused cotyledons. We additionally measured in the perfused placentas folic acid concentrations and histone acetylation. Results: VPA significantly altered the mRNA levels of major carriers for folic acid, glucose, choline, thyroid hormones, and serotonin (P < .05) and reduced placental folate concentrations by 25%-35% (P = .059). The effects were observed at therapeutic concentrations sufficient to enhance placental histone acetylation, and some were concentration-dependent. Significance: Our results point to the placenta as a novel target of VPA, implying potential involvement of the placenta in VPA's adverse fetal outcomes.
| INTRODUCTION
Since the early 1980s, in utero exposure to valproic acid (VPA) has been shown to be associated with adverse fetal outcomes. These include fetal loss, impaired growth, major congenital malformations (MCMs), and minor anomalies. 1, 2 The risk of MCMs associated with VPA treatment was 2-7 times as high compared with other antiepileptic drugs (AEDs) and was dose-dependent, although extensive variability in serum concentrations has been demonstrated in women of childbearing age 3 and during pregnancy. 4 VPA use was also associated with increased risk of autism spectrum disorders 5 and impaired cognitive outcomes of the offspring. Particularly, the NEAD study demonstrated that children at ages 3 years 6 and 6 years 7 exposed to VPA in utero had intelligence quotients (IQs) 6-10 points lower, as compared to children exposed to other AEDs. These outcomes also depended on the dose, with no reduction in IQ with maternal use of VPA at doses < 1000 mg/d. A related study confirmed the effect of in utero exposure to VPA on the child's IQ, but also demonstrated that even doses < 800 mg/d were associated with a 6-fold increased need for educational intervention and with reduced verbal abilities compared with controls. 8 These observations led to has to be prescribed to some pregnant women with epilepsy, there is a need for better understanding of the mechanisms by which this drug affects fetal development, to minimize its harmful effects. Recently, we have shown that VPA alters the expression of carriers for nutrients, hormones, and medications in a human placental cell line 12 and in pregnant mice. 13 Another study demonstrated direct inhibition by VPA of folate binding to its receptors in vitro. 14 The aim of the current study was to explore, for the first time, the effects of VPA on the human placental barrier ex vivo, under controlled conditions. We exposed to VPA cotyledons obtained through cesarean deliveries from women with no known epilepsy through perfusion over 180 minutes. This short timeline allowed us to evaluate early effects of VPA at therapeutic (42 lg/mL and 83 lg/ mL 3, 4, 15 ) and supratherapeutic (166 lg/mL) concentrations on the expression of placental carriers, as well as potential direct inhibition of folate uptake into placental syncytiotrophoblasts. The supratherapeutic concentration was chosen to extend the range of the concentration-response analysis and to represent possible excessive drug effects (eg, following overdose intake). Histone acetylation was used as a marker of VPA interaction with transcriptional mechanisms.
| MATERIALS AND METHODS

| The placentas
The study was approved by the Edith Wolfson Medical Center Helsinki Committee (protocol 0040-10-WOMC). Written informed consent was obtained from participants prior to delivery, and all the procedures were in accordance with the ethical standards of the responsible committee on human experimentation or with the Helsinki Declaration of 1975 (as revised in 1983). Placentas were collected immediately after elective cesarean deliveries. Prior to perfusion, placentas were carefully inspected and those with visible tears were discarded.
| Perfusion of placental cotyledons
The placental perfusion system contained 2 independent maternal and fetal perfusion circuits that individually maintained stable pH, temperature, and flow rates during the dual-perfusion process. Perfusion studies were conducted as described before with some modifications, using a closed-circuit configuration. 16, 17 Briefly, a single cotyledon was isolated and cannulated within 20 minutes after delivery. Fetal circulation was established by cannulation of the fetal artery and vein from a selected cotyledon of each placenta. Following cannulation, the cotyledon was perfused with heparinized Krebs-Ringer solution (500 mL; Teva, Ashdod, Israel). After having verified proper flow and absence of leakage, the cotyledon was mounted in the perfusion chamber. The maternal circulation was created by placing 3 blunt needles into the intervillous space of the lobe of the isolated cotyledon and ongoing perfusion. The cotyledon was first perfused in open circuit for a control period of 30 minutes, with heparinized Krebs-Ringer solution to stabilize the tissue, remove the blood, and exclude any leakage. The perfusion solution was then replaced by tissue culture medium M199 (Sterile Earle's salt base with L-glutamate; Biological Industries, Beit Haemek, Israel) enriched with 30 g/L bovine serum albumin, 1 g/L glucose, 10 IU/mL heparin, and 48 lg/mL gentamicin, which was maintained at 37°C and perfused in open circuit for another 30 minutes. The fetal perfusate (250 mL) was equilibrated with 95% N 2 /5% CO 2 to mimic the low oxygen tensions observed in utero, whereas the maternal perfusate (250 mL) was equilibrated with 95% O 2 /5% CO 2 . Sodium bicarbonate or HCl was added to maintain the perfusate pH within a physiologic range (7.35-7.45) . Perfusion rate was 10-12 mL/min and 6-8 mL/min in maternal and fetal circulations, respectively. During the entire perfusion period, lateral pressure was measured by a pressure transducer (GE Medical Systems, Milwaukee, WI, USA) in the fetal inflow line next to the point of cannulation. Proper flow was defined by the ability to achieve adequate circuit perfusion rates as described above, within fetal perfusion pressure of 20-70 mm Hg. After 60 minutes of open perfusion during which blood was washed out and stable perfusion parameters were achieved, the perfusion circuit was closed and the maternal perfusate was replaced with either M199 medium enriched with additives as described above for the control group (n = 7) or the same medium additionally containing
Key Points
• VPA affects the expression of multiple carriers for essential compounds at the human placenta in a concentration-dependent manner
• Affected carriers include those for folate, glucose, and serotonin
• At therapeutic levels, VPA enhances placental histone acetylation, thereby potentially affecting expression of additional placental genes sodium VPA (42 lg/mL, 0.25 mmolÁL -1 ; 83 lg/mL, 0.5 mmolÁL -1 ; or 166 lg/mL, 1 mmolÁL -1 ; dissolved in double distilled water (final concentration in the medium 0.2%; n = 7 for each group). The cotyledon was perfused for an additional 180 minutes. The presence of human chorionic gonadotropin beta (bhCG) in the fetal reservoir during the perfusion was evaluated using a simple stick pregnancy test (Innovacon, San Diego, CA, USA). At the end of the perfusion experiment, a bolus of 2.5 mg prostaglandin E2 (PE2; dinoprostone; Pfizer, Puurs, Belgium) was added to the fetal arterial side, next to the point of cannulation, and the fetal vasculature response was recorded.
Control over the quality of each perfusion was maintained by (1) ability to achieve adequate circuit perfusion rates within fetal perfusion pressure during the entire perfusion period ranging 20-70 mm Hg; (2) absence of detectable bhCG in the fetal reservoir during the perfusion; (3) increase in fetal inflow pressure > 20% of baseline, following administration of PE2 at the end of the perfusion experiment; and (4) the rate of perfusate input in both maternal and fetal circuits equaled the output rate.
At the end of the perfusion, tissue samples were collected from each perfused cotyledon for evaluation of carrier expression in placental tissue. Tissue samples were stored at À80°C until analysis.
| Total RNA extraction
Small tissue pieces, approximately 30 mg each (coefficient of variation < 10%), were cut out of each placental sample. Samples were washed 2 times with cold phosphate-buffered saline to remove remains of blood and medium. Total mRNA was isolated using the RNeasy mini-isolation kit (Qiagen, Hilden, Germany). The pieces were placed into 2-mL Eppendorf tubes containing mixed-sized stainlesssteel beads and homogenized according to instructions of the kit's manufacturer using a Bullet Blender Homogenizer (Next Advance, Averill Park, NY, USA). RNA integrity and purity were verified by ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) based on ratios of absorption at 260/280 nm and 230/280 nm of 2.07 (2.05-2.1) and 1.9 (1.5-2.1), respectively.
| Gene expression assays
For expression analysis across a gene array, we used the nCounter gene expression assay (NanoString Technologies, Seattle, WA, USA), which captures and counts individual mRNA transcripts, 18 using mRNA samples with no treatment group identifiers. Primers were constructed to the genes of interest. Raw gene expression count data were normalized against the geometric mean of spikes in positive control probes and against the geometric mean of 3 housekeeping genes-hypoxanthine phosphoribosyltransferase 1, TATAbox binding protein, and b-actin. Samples with normalized count < 50 were considered as below limit of detection. Changes in the expression levels of target genes from the VPA-treated groups were than normalized to those of the vehicle control group. Regions and targets with similar profiles were identified using a hierarchically clustered heatmap of normalized digital counts. Quantitative real-time polymerase chain reaction was used to validate the nCounter gene expression data for selected carriers as previously described. 12 Briefly, cDNA was synthesized from 1 lg of total RNA. Reverse transcription was performed using TaqMan reverse transcription reagents (Applied Biosystems, Branchburg, NJ, USA). The reactions were run as follows: 25°C for 10 minutes, followed by 37°C for 120 minutes, then 85°C for 5 minutes. Real-time polymerase chain reaction (PCR) assay was carried out with the use of gene specific 6-carboxy-fluorescein (FAM)-labeled fluorescent minor groove binder (MGB) probes in the StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA, USA) on a fast mode. Four samples from each placenta were run in duplicate. The reaction final volume was 10 lL for each sample. The relative mRNA levels in each sample were normalized to the housekeeping gene b-actin. Changes in mRNA expression of target genes from the VPA-treated groups were expressed relative to that of the vehicle control group.
| Determination of tissue folate and glucose concentrations
Tissue samples were weighed and transferred to test tubes, containing saline at a 1:10 ratio (mg:lL) and mixed-sized stainless steel beads. The samples were homogenized as described above. Ten percent sodium dodecyl sulfate (SDS) was then added to the homogenized samples. All samples were centrifuged, and the supernatant was collected. For folate assay, the samples were further diluted 1:10 in saline, to meet the assay's accuracy range. Folate concentration in the placental tissue was obtained using Elecsys folate assay (cobas; Roche Diagnostics, Indianapolis, IN, USA). The assay was conducted at the Hadassah Medical Center's laboratories of clinical biochemistry (Jerusalem, Israel).
| Histone acetylation studies
Samples of~100 mg from each placenta were cut into small pieces (coefficient of variation < 10%) and homogenized as described above, and histones were extracted using a histone extraction kit (Abcam, Cambridge, UK), according to the manufacturer's instructions. Protein concentrations were determined by a bovine serum albumin (BSA) protein assay kit (Pierce, Rockford, IL, USA), using BSA as a standard. Samples were then mixed with SDS sample buffer and subjected to SDS-polyacrylamide gel electrophoresis. Stacking and separating gels were made of 5% and 17.5% acrylamide, respectively. Each lane was loaded with 10 lg protein samples. Following separation, the proteins from the gels were transferred to nitrocellulose membranes using a Mini Trans-Blot Cell (Bio-Rad Laboratories, Hercules, CA, USA). Membranes were blocked in Tris-buffered saline containing 0.1% Tween 20 and 5% skim milk powder (Difco, Franklin Lakes, NJ, USA) and probed for 1 hour at room temperature with primary antibodies (Abcam) against b-actin (1:1000), histone H4 (1:20 000), and histone H3 (1:500). The blots were incubated for 1 hour with horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) at 1:10 000 dilutions and developed by enhanced chemiluminescence. b-Actin was used as the internal control.
| Statistical analysis
The Kruskal-Wallis test followed by Dunn posttest was used to determine the statistical significance (P < .05) of the differences between experimental groups (InStat; GraphPad, La Jolla, CA, USA). Data are presented as median and interquartile range.
3 | RESULTS
| The characteristics of pregnancies and placentas do not differ across treatment groups
The clinical characteristics of the pregnancies and placental cotyledons are presented in Table 1 . The treatment groups did not significantly differ in terms of maternal age, week of gestation, birth weight, and the weight of the perfused cotyledon (P > .05). The fetal arterial pressure and the fetal and maternal pH of the perfusates were stable throughout the perfusion experiment with no significant differences between the treatment groups ( Table 2) . Following PE2 injection to the fetal arterial line, the perfusion pressure was elevated to a similar extent across all groups (P > .05). b-hCG was not detectable in the fetal reservoir during the perfusion in any of the perfusion studies.
| VPA alters the transcript levels of key placental carriers
The nCounter gene expression assay demonstrated that perfusion with therapeutically relevant concentrations of VPA alters the gene expression of major placental carriers for compounds essential for fetal growth and development (Table 3) . Expression of FOLR1, encoding the folate receptor a, was down-regulated by 57% and 72% (P < .05) in the presence of 83 and 166 lg/mL VPA, respectively. Similar trends were observed for carriers of glucose (SLC2A1; glucose transporter 1 [GLUT1]; P < .05), choline (SLC44A1; choline transporter-like 1 [CTL1]; P < .05), and thyroid hormones and amino acids (SLC7A8; L-type amino acid transporter 2; P < .05). Expression of the serotonin transporter SLC6A4 and the organic anion transporter 4 (SLC22A11) was up-regulated by >50% (P < .05).
A hierarchically clustered heatmap was generated based on the data of the 24 women who were included in the study. Additional 4 women whose placentas were excluded from the other analyses were included to enrich the database ( Figure 1A) . Three of these women were treated with insulin for gestational diabetes mellitus. Another patient was treated with metoprolol due to chronic hypertension. The same patient additionally had a history of recurrent pregnancy loss, was found to be homozygous for a methyl tetrahydrofolate reductase mutation, and was treated with folic acid 5 mg/d and enoxaparin. The cluster analysis revealed interesting patterns of gene expression and coregulation by VPA ( Figure 1A ). For example, FOLR1 was clustered together with SLC46A1 (the proton-coupled folate transporter [PCFT]), SLC44A1, and SLC2A1, with similar effect of VPA on their expression (Figure 1B-E) . The expression of another folate transporter, SLC19A1 (the reduced folate carrier), was not closely related to those of FOLR1 and SLC46A1. Likewise, ABCB1 (P-glycoprotein) and ABCG2 (the breast cancer resistance protein) appeared to be coregulated by VPA ( Figure 1A ). These patterns can be also observed in Table 3 and Figure 1B -E, in which the data do not represent the 4 additional women.
Folate concentrations within placental tissue exposed to VPA were reduced to 75%, 65%, and 68% of control in the presence of 42, 83, and 166 lg/mL VPA, respectively, but the reduction was not statistically significant (P = .059; Figure 2 ). VPA significantly enhanced the acetylation of histones H3 and H4 by up to~2.5-fold (Figure 3 ).
| PCR analysis supports the nCounter data
To validate the gene panel expression data, we used quantitative real-time PCR for 6 genes (ABCB1, ABCG2, SLC2A1, SLC19A1, SLCO4A1, and PPARG). Both approaches pointed to similar directions of change (up-or down-regulation) except for ABCG2, although the magnitude of change was consistently higher using the PCR analysis ( Figure S1 ).
| DISCUSSION
The important role of the placenta in fetal development has been highlighted in a recent report of the U.S. National Institute of Child Health and Human Development, which states that "most adverse pregnancy outcomes can trace their origins to the placenta." 19 However, very few studies have investigated the placenta as a target of adverse pregnancy outcomes of medications. 20 The current study demonstrates changes in placental carrier expression that occur rapidly (within hours) after perfusion with VPA. We used perfused placentas from women with no known epilepsy (Table 1) to isolate the effects of VPA from those of epilepsy.
| Key placental carriers are targets of VPA
Remarkably, VPA affected the expression of major folate carrier genes, with significant down-regulation of FOLR1 expression and a tendency toward reduced levels of SLC46A1 (PCFT) transcripts. Expression of another folate uptake carrier, SLC19A1, was up-regulated. These changes were not expected to translate into altered carrier protein activity within the 3 hours of perfusion. Yet our analysis revealed a tendency toward reduced folate accumulation (~35%) in placentas exposed to VPA (Figure 2 ), possibly due to direct inhibition of placental folate uptake. 14 These changes in placental folate handling, if translated to placental-fetal folate kinetics in vivo, may lead to reduced transfer of folates to the fetus, especially when the magnitude of change is greater than the average. Interestingly, in the NEAD study, periconceptional folate appeared to have beneficial effects on cognitive development following in utero exposure to AEDs, but the weakest effect was found among women treated with VPA. 7 Similar to FOLR1, the major placental glucose transporter SLC2A1 (GLUT1) was also significantly down-regulated by VPA. Fetal production of glucose is minimal, and the fetus completely depends on the glucose supply from the maternal circulation. 21 Reduced glucose transport to the fetus is associated with impaired fetal growth, [22] [23] [24] which has been reported as a fetal outcome of AED treatment.
2,25
Furthermore, infants exposed to VPA during pregnancy had a significantly increased risk of hypoglycemia,
T A B L E 1 Clinical characteristics of the studied pregnancies and placentas
Control, n = 6 4 2 lg/mL VPA, n = 6 83lg/mL VPA, n = 6 166 lg/mL VPA, n = 6 Vaginal progesterone tablets were used as a preventive treatment due to a history of a preterm birth. This treatment was discontinued at 35 weeks of gestation.
c Each twin gestation was represented by a single placenta, such that the number of pregnancies in each group was 6.
T A B L E 2 Viability parameters of the studied placentas
Control, n = 6 4 2lg/mL VPA, n = 6 8 3lg/mL VPA, n = 6 166 lg/mL VPA, n = 6 which was attributed to VPA withdrawal symptoms after birth. [26] [27] [28] Our results suggest that the hypoglycemia could have presented already in utero due to reduced glucose transfer to the fetus.
VPA additionally reduced the mRNA levels of the main placental choline uptake transporter CTL1. 29 If a similar reduction occurs in pregnant women, it may lead to depletion of choline in the fetal compartment and placenta itself.
T A B L E 3 Transcript levels in the perfused placentas (percent of control)
Gene symbol (protein) 42 lg/mL, n = 6 8 3lg/mL, n = 7 166 lg/mL, n = 6 P total Values are presented as percentage of control (mean values). Samples with normalized count values < 50 were excluded. Low count values (<50) were obtained for 3 or more samples of SLC28A1 (concentrative nucleotide transporter 2), SLC38A4 (SNAT4), SLCO1A2 (OATP1A2), SLC47A1 (multidrug and toxin extrusion protein 1), and SLC47A2 (multidrug and toxin extrusion protein 2). These analyses are not shown. P total , P value across all groups. The bold font indicates genes encoding uptake carriers and associated subunits for folate (FOLR-1, RFC, PCFT), glucose (GLUT1), choline (CTL1 and 2), amino acids (LAT1 and 2, the LAT subunit), and serotonin (SERT). AHR, aryl hydrocarbon receptor; BCRP, breast cancer resistance protein; CTL, choline transporter-like; ENT, equilibrative nucleoside transporter; FATP, fatty acid transporting protein; FOLR, folate receptor; GLUT, glucose transporter; GR, glucocorticoid receptor; LAT, L-type amino acid transporter; MRP, multidrug resistance-associated protein; NET, norepinephrine transporter; OAT, organic anion transporter; OATP, organic anion-transporting polypeptide; OCT, organic cation transporter; OCTN, novel organic cation transporter; PCFT, proton-coupled folate transporter; P-gp, P-glycoprotein; PPAR, peroxisome proliferator-activated receptor; RFC, reduced folate carrier; SERT, serotonin transporter; SNAT, sodium-coupled neutral amino acid transporter; TAUT, taurine transporter; TCblR, transcobalamin II receptor; VDR, vitamin D receptor.
a One sample was excluded from the analysis due to low normalized count value.
Previously, periconceptional choline supplementation was shown to reduce the risks of neural tube defects 30 and orofacial clefts 31 and had a beneficial effect on cognitive development. 32 Another interesting observation is the up-regulated (>1.5-fold) expression of SLC6A4, encoding the serotonin transporter. The fetus completely depends on maternal serotonin, which is important in early stages of morphogenesis and is critical for fetal brain development. 33 In the early 1960s, elevated serotonin levels were reported in children diagnosed with autism. 34 Later on, it was suggested that The heatmap was generated with data from all the studied placentas and additional placentas from 4 women; 3 were treated with insulin for gestational diabetes mellitus (1 in each of the control, 42 lg/mL, and 166 lg/mL groups; indicated by open arrows); 1 (in the 83 lg/mL group; indicated by black arrow) had hypertension, a history of recurrent pregnancy loss, and was homozygous for a methyltetrahydrofolate reductase mutation. She was treated daily with 5 mg folic acid, enoxaparin, and metoprolol. The placentas of those 4 women were not included in the other analyses. B-E, Relative expression of representative carriers (1 woman excluded from each treatment group, as described in the text). B, FOLR1 (folate receptor a). C, SLC2A1 (glucose transporter 1). D, SLC44A1 (choline transporter-like 1). E, SLC46A1 (proton-coupled folate transporter). Relative mRNA levels of vehicle controls are set as 100%. Results are presented as median and interquartile range from 6 placentas (in duplicate) in each experimental group. *P < .05. The asterisk in D denotes a statistically significant difference across groups. However, the Dunn post hoc test did not identify groups that differ from the others elevated levels of serotonin in early stages of brain development may cause loss of serotonin terminals via negative feedback, which may lead to some of the cellular and behavioral changes associated with autism.
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The bell-shaped concentration-effect analysis of SLC6A4 and several other transporters (eg, SLC22A1) observed in our study are unlikely to reflect reduced placental viability at the time of measurement, because the VPA-treated placentas preserved viability parameters similar to those of control placentas (Table 2 ). This pattern may rather be explained by alternative mechanisms that are activated (or inhibited) at higher VPA concentrations.
| VPA's effects on carrier expression may be concentration-dependent
Many of the effects of VPA on carrier expression were significant only at concentrations representing high therapeutic or supratherapeutic levels of the drug. These findings are clinically relevant, because some adverse fetal effects of VPA depend on the dose. 6, 7, 36, 37 The heatmap demonstrated that placental genes encoding uptake carriers were coexpressed in groups and patterns, suggesting they may be coordinately regulated, as was described before. 38 For instance, in cell and tissue types other than the placenta, the phosphoinositide 3-kinase/Akt pathway regulates the expression of the glucose transporter GLUT1, 39 the 4F2hc subunit (SLC3A2) of the heterodimeric amino acid transporters LAT1 (SLC7A5)/4F2hc and xCT (SLC7A11), 40 and other carriers. 41 Likewise, both diabetes and insulin can regulate the expression of several placental carriers. 42 The exact mechanisms by which VPA exerts its early effects on placental carrier expression (or mRNA degradation), as well as the mechanisms activated upon chronic exposure to VPA, have yet to be clarified.
| Concordance and variation across experimental models
Although many of the current findings are in line with our data from BeWo cells 12 and in mouse placentas, 13 some differences were noted. The expression of SLC19A1 in the perfused human placenta was enhanced following exposure to VPA, in contrast to the observed reduction in its levels in BeWo cells, and FOLR1 expression in BeWo cells increased following incubation with VPA, whereas in the perfused human placenta the expression was down-regulated. Notably, our current study assessed the early changes following 3 hours of VPA exposure, compared to exposure over several days in our previous analyses. In addition, the patterns and pathways of carrier expression may differ across experimental models. 43 
| Study limitations and strengths
Several limitations of this study should be considered. First, perfusion was performed using term placentas. The expression of some placental carriers changes with gestational age, 20, 44 meaning that regulation of their expression in term placentas may differ from that of first trimester placentas when organogenesis takes place. Therefore, whether the findings observed in term placentas reflect similar changes that may occur during early pregnancy is yet unknown and requires studying the effects of VPA on placentas collected during early pregnancies. However, changes in the activity of carriers for compounds that affect the development of the central nervous system and fetal growth (eg, glucose, serotonin) are relevant during late pregnancy as well. Second, we limited our analysis to 3 hours of perfusion, which represent only early changes in gene expression following VPA exposure. However, we are currently evaluating the effects of longer-term exposure of the human placenta to VPA using other experimental models. Third, we did not evaluate the impact of VPA metabolites on carrier expression. Such studies are clearly required, to determine whether VPA's metabolites contribute to its placental effects in vivo. Finally, we did not measure the placental concentrations of VPA. However, enhanced histone acetylation indicated that the drug achieves concentrations high enough to inhibit histone deacetylase, [45] [46] [47] thereby potentially regulating carrier (and other gene) expression. 48, 49 To our knowledge, this study for the first time demonstrates that VPA, at therapeutic concentrations, inhibits histone deacetylation in the human placenta. Despite the abovementioned limitations, our model has several advantages. The studies were conducted in human placentas, under controlled conditions that best mimic the exposure to VPA during pregnancy because syncytiotrophoblasts are exposed to the drug from placental circulation, and VPA has been shown to efficiently cross the placenta. 20 In addition, expression measurements were conducted in several samples from each placenta, thus partially overcoming the variability within placental tissue. 17 Furthermore, we evaluated the effects of VPA over a concentration range spanning its therapeutic and toxic levels in humans.
| CONCLUSIONS
Even short exposure of the human placenta to VPA is sufficient for triggering changes in the expression of carriers for compounds essential for fetal growth and development. These findings suggest a new mechanism for adverse developmental outcomes in VPA-exposed fetuses.
